CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 192 filers reported holding CATALYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $806,566 | +67.1% | 68,998 | +92.1% | 0.00% | 0.0% |
| Q2 2023 | $482,550 | -37.8% | 35,912 | -23.2% | 0.00% | 0.0% |
| Q1 2023 | $775,501 | +34.4% | 46,779 | +50.7% | 0.00% | 0.0% |
| Q4 2022 | $577,115 | +91.1% | 31,042 | +31.6% | 0.00% | 0.0% |
| Q3 2022 | $302,000 | +2416.7% | 23,586 | +1284.2% | 0.00% | – |
| Q2 2022 | $12,000 | +20.0% | 1,704 | +42.4% | 0.00% | – |
| Q1 2022 | $10,000 | +25.0% | 1,197 | +2.5% | 0.00% | – |
| Q4 2021 | $8,000 | +14.3% | 1,168 | -7.4% | 0.00% | – |
| Q3 2021 | $7,000 | +16.7% | 1,262 | +13.7% | 0.00% | – |
| Q2 2021 | $6,000 | +50.0% | 1,110 | +20.8% | 0.00% | – |
| Q1 2021 | $4,000 | +300.0% | 919 | +359.5% | 0.00% | – |
| Q4 2020 | $1,000 | -85.7% | 200 | -90.5% | 0.00% | – |
| Q3 2020 | $7,000 | +133.3% | 2,100 | +200.0% | 0.00% | – |
| Q2 2020 | $3,000 | -25.0% | 700 | -30.0% | 0.00% | – |
| Q1 2020 | $4,000 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |